Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, will present at the American Association of Cancer Research (AACR) Virtual Annual Meeting II, occurring June 22 – 24, 2020.
The AACR poster, by the AST-008 Phase 1b/2 study investigators and Exicure, titled “Phase 1b/2 Study of an Intratumoral TLR9 Agonist Spherical Nucleic Acid (AST-008) and Pembrolizumab: Evidence of Immune Activation” will present updated pharmacodynamic and safety data of AST-008 alone and in combination with pembrolizumab from Exicure’s ongoing Phase 1b/2 study (ClinicalTrials.gov identifier: NCT03684785). AST-008 is a novel SNA configuration of a toll-like receptor 9 (TLR9) agonist oligonucleotide, designed to trigger anti-tumor immune responses.
Data to be presented include:
- Gene expression analysis from biopsied tumors, showing trends to increased lymphocytes in the injected tumor after intratumoral (IT) AST-008 and in both injected and un-injected tumors after IT AST-008 plus pembrolizumab combination therapy
- Dose dependent activation of key immune cells and immune system signal proteins (cytokines/chemokines) after IT AST-008 treatment and AST-008 plus pembrolizumab treatment
- An emerging safety profile consisting of mostly injection site reactions and flu-like symptoms, likely reflecting local and systemic immune activation
- No AST-008-related serious adverse events or dose limiting toxicity have been reported
This poster will be presented during the AACR Virtual Meeting II in the session Late-Breaking Research: Clinical Research 1 / Endocrinology under abstract number LB-140. The poster will be available for viewing starting on June 22nd.